Horizon Pharma (HZNP) Rating Lowered to Hold at ValuEngine

Horizon Pharma (NASDAQ:HZNP) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

HZNP has been the topic of a number of other research reports. Cantor Fitzgerald set a $17.00 price objective on Horizon Pharma and gave the company a “buy” rating in a report on Monday, January 8th. Stifel Nicolaus reissued a “buy” rating and set a $20.00 price objective on shares of Horizon Pharma in a report on Sunday, October 22nd. Jefferies Group reissued a “buy” rating and set a $16.00 price objective on shares of Horizon Pharma in a report on Thursday, October 5th. UBS Group set a $20.00 price objective on Horizon Pharma and gave the company a “buy” rating in a report on Thursday, November 30th. Finally, BidaskClub raised Horizon Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $19.25.

Horizon Pharma (NASDAQ HZNP) opened at $14.45 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. The company has a market capitalization of $2,368.15, a PE ratio of -4.74, a PEG ratio of 0.68 and a beta of 1.35. Horizon Pharma has a fifty-two week low of $9.45 and a fifty-two week high of $17.69.

Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.04. The business had revenue of $271.60 million for the quarter, compared to analyst estimates of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The firm’s revenue for the quarter was up 30.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.70 EPS. analysts expect that Horizon Pharma will post 0.72 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the stock. James Investment Research Inc. bought a new stake in Horizon Pharma during the 4th quarter valued at approximately $1,920,000. Fox Run Management L.L.C. boosted its stake in Horizon Pharma by 21.5% during the 4th quarter. Fox Run Management L.L.C. now owns 19,200 shares of the biopharmaceutical company’s stock valued at $280,000 after purchasing an additional 3,400 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in Horizon Pharma by 3.3% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 878,801 shares of the biopharmaceutical company’s stock valued at $12,831,000 after purchasing an additional 28,451 shares during the period. California Public Employees Retirement System boosted its stake in Horizon Pharma by 3.4% during the 3rd quarter. California Public Employees Retirement System now owns 325,085 shares of the biopharmaceutical company’s stock valued at $4,122,000 after purchasing an additional 10,585 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its stake in Horizon Pharma by 878.1% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 49,493 shares of the biopharmaceutical company’s stock valued at $628,000 after purchasing an additional 44,433 shares during the period. Hedge funds and other institutional investors own 85.99% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.com-unik.info/2018/02/04/horizon-pharma-hznp-rating-lowered-to-hold-at-valuengine.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit